Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

Reassessment of antibiotic therapy in hospitals.

Lucas M, Germain JM, Rémy E, Lottin M, Etienne M, Czernichow P, Merle V.

Med Mal Infect. 2017 May 24. pii: S0399-077X(17)30139-7. doi: 10.1016/j.medmal.2017.03.003. [Epub ahead of print]

PMID:
28550938
2.

Poster 292 Improvement of Spasticity Following AbobotulinumtoxinA (Dysport®) Injections in Shoulder Muscles in Hemiparetic Patients with Upper Limb Spasticity-Sub-Analysis of a Prospective, Long-Term, Open-Label Study with Single and Repeated Injection Cycles.

Gul F, O'Dell M, Jech R, Banach M, Vilain C, Grandoulier AA, Germain JM, Graciès JM.

PM R. 2016 Sep;8(9S):S255. doi: 10.1016/j.pmrj.2016.07.465. Epub 2016 Sep 24. No abstract available.

PMID:
27673048
3.

Retreatment in patients with psoriasis achieving response with etanercept after relapse due to treatment interruption: results from the CRYSTEL study.

Griffiths CE, Luger TA, Brault Y, Germain JM, Mallbris L.

J Eur Acad Dermatol Venereol. 2015 Mar;29(3):468-73. doi: 10.1111/jdv.12585. Epub 2014 Aug 4.

PMID:
25087839
4.

Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept.

Griffiths CE, Sterry W, Brock F, Dilleen M, Stefanidis D, Germain JM, Mallbris L.

Br J Dermatol. 2015 Jan;172(1):230-8. doi: 10.1111/bjd.13139. Epub 2014 Nov 13.

PMID:
24861696
5.

Etanercept reduces symptoms and severity of psoriasis after cessation of cyclosporine therapy: results of the SCORE study.

Micali G, Wilsmann-Theis D, Mallbris L, Gallo G, Marino V, Brault Y, Germain JM.

Acta Derm Venereol. 2015 Jan;95(1):57-61. doi: 10.2340/00015555-1845.

6.

A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis.

Ortonne JP, Paul C, Berardesca E, Marino V, Gallo G, Brault Y, Germain JM.

Br J Dermatol. 2013 May;168(5):1080-7. doi: 10.1111/bjd.12060.

PMID:
23013207
7.

Investigation of a severe nosocomial outbreak of hepatitis A among healthcare workers and adult patients.

Guet L, Desbois D, Roque-Afonso AM, Germain JM, Merle V.

J Hosp Infect. 2011 May;78(1):70-1. doi: 10.1016/j.jhin.2010.11.010. Epub 2011 Jan 31. No abstract available.

PMID:
21277653
8.

HAM-D17 and HAM-D6 sensitivity to change in relation to desvenlafaxine dose and baseline depression severity in major depressive disorder.

Bech P, Boyer P, Germain JM, Padmanabhan K, Haudiquet V, Pitrosky B, Tourian KA.

Pharmacopsychiatry. 2010 Nov;43(7):271-6. doi: 10.1055/s-0030-1263173. Epub 2010 Sep 9.

PMID:
20830664
9.

Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trial.

Rickels K, Montgomery SA, Tourian KA, Guelfi JD, Pitrosky B, Padmanabhan SK, Germain JM, Leurent C, Brisard C.

J Clin Psychopharmacol. 2010 Feb;30(1):18-24. doi: 10.1097/JCP.0b013e3181c94c4d.

PMID:
20075643
10.

Non-compliance with recommendations for the practice of antibiotic prophylaxis and risk of surgical site infection: results of a multilevel analysis from the INCISO Surveillance Network.

Miliani K, L'Hériteau F, Astagneau P; INCISO Network Study Group.

J Antimicrob Chemother. 2009 Dec;64(6):1307-15. doi: 10.1093/jac/dkp367. Epub 2009 Oct 16.

PMID:
19837713
11.

An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder.

Thase ME, Kornstein SG, Germain JM, Jiang Q, Guico-Pabia C, Ninan PT.

CNS Spectr. 2009 Mar;14(3):144-54. Review.

PMID:
19407711
12.

Influence of infection control report cards on patients' choice of hospital: pilot survey.

Merle V, Germain JM, Tavolacci MP, Brocard C, Chefson C, Cyvoct C, Edouard S, Guet L, Martin E, Czernichow P.

J Hosp Infect. 2009 Mar;71(3):263-8. doi: 10.1016/j.jhin.2008.11.025. Epub 2009 Jan 14.

PMID:
19147258
13.

Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial.

Boyer P, Montgomery S, Lepola U, Germain JM, Brisard C, Ganguly R, Padmanabhan SK, Tourian KA.

Int Clin Psychopharmacol. 2008 Sep;23(5):243-53. doi: 10.1097/YIC.0b013e32830cebed.

PMID:
18703933
14.

A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder.

Lieberman DZ, Montgomery SA, Tourian KA, Brisard C, Rosas G, Padmanabhan K, Germain JM, Pitrosky B.

Int Clin Psychopharmacol. 2008 Jul;23(4):188-97. doi: 10.1097/YIC.0b013e32830263de.

PMID:
18545056
15.

A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.

Septien-Velez L, Pitrosky B, Padmanabhan SK, Germain JM, Tourian KA.

Int Clin Psychopharmacol. 2007 Nov;22(6):338-47.

PMID:
17917552
16.

Patient-to-patient transmission of hepatitis C virus through the use of multidose vials during general anesthesia.

Germain JM, Carbonne A, Thiers V, Gros H, Chastan S, Bouvet E, Astagneau P.

Infect Control Hosp Epidemiol. 2005 Sep;26(9):789-92.

PMID:
16209386
17.

MMPI-2 profile code types and measurement error.

Munley PH, Germain JM, Tovar-Murray D, Borgman AL.

J Pers Assess. 2004 Apr;82(2):179-88.

PMID:
15041524
18.

Nosocomial urinary tract infections in urologic patients: assessment of a prospective surveillance program including 10,000 patients.

Merle V, Germain JM, Bugel H, Nouvellon M, Lemeland JF, Czernichow P, Grise P.

Eur Urol. 2002 May;41(5):483-9.

PMID:
12074789
19.

Comparison of two methods of MMPI-2 profile classification.

Munley PH, Germain JM.

Psychol Rep. 2000 Oct;87(2):515-22.

PMID:
11086595
20.

[Impact of the daily variations of the air pollution on the ambulatory emergency health services activity. Study in the urban area of Rouen (France)].

Hautemanière A, Czernichow P, Germain JM, Delmas V, Falourd JC, Zeghnoun K, Dureuil B.

Rev Epidemiol Sante Publique. 2000 Oct;48(5):449-58. French.

PMID:
11084525

Supplemental Content

Loading ...
Support Center